(Albany, US) DelveInsight launched a new report on Pulmonary Arterial Hypertension Market Insights, Epidemiology and Market Forecast-2030
DelveInsight’s “Pulmonary Arterial Hypertension (PAH) – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Pulmonary Arterial Hypertension (PAH) , historical and forecasted epidemiology as well as the Pulmonary Arterial Hypertension (PAH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the report:
1. Pulmonary Arterial Hypertension prevalence was observed to be 109 per million individuals among the population of fewer than 65 years old. 2. Approximately 16.2% of patients are newly diagnosed with Pulmonary Arterial Hypertension. The overall prevalence of Pulmonary Hypertension was found to be 19.2 cases per Million Adult Inhabitants (MAI) among the Spanish population. 3. In 2017, the total prevalent cases of Pulmonary Arterial Hypertension were 70,774 in the seven major markets.
Key benefits of the report
1. Pulmonary Arterial Hypertension market report covers a descriptive overview and comprehensive insight of the Pulmonary Arterial Hypertension Epidemiology and Pulmonary Arterial Hypertension market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.) 2. Pulmonary Arterial Hypertension market report provides insights into the current and emerging therapies. 3. Pulmonary Arterial Hypertension market report provides a global historical and forecasted market covering drug outreach in 7 MM. 4. Pulmonary Arterial Hypertension market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Pulmonary Arterial Hypertension market.
“The disease is found to be more common among women as compared to men.”
Request for Free Sample: https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pah-market
Pulmonary Arterial Hypertension therapeutic market is driven by the use of endothelin receptor antagonists, prostanoids, and phosphodiesterase inhibitors for the Pulmonary Arterial Hypertension treatment. Among these therapeutics endothelin receptor antagonists are most widely used for the treatment of Pulmonary Arterial Hypertension.
LetairisVolibris(GlaxoSmithKline plcGilead Science), Opsumit (Actelion Pharmaceuticals Ltd), and Tracleer (Actelion Pharmaceuticals Ltd) are mostly recommended endothelin receptor antagonists being used for the Pulmonary Arterial Hypertension treatment. These antagonists act by relaxing blood vessels and inhibiting proliferation and remodelling of blood vessels. LetairisVolibris (GlaxoSmithKline plcGilead Science), which is a selective Endothelin Type-A (ETA) receptor antagonist is the most robust therapeutic as compared to the other endothelin receptor antagonists (ERAs).
Tracleer (Actelion Pharmaceuticals Ltd) is the first endothelin receptor antagonists being approved by the US FDA for treating Pulmonary Arterial Hypertension. Opsumit (Actelion Pharmaceuticals Ltd) is a tissue- targeting endothelin receptor antagonist indicated explicitly for the treatment of pulmonary arterial hypertension (WHO Group I) to delay disease progression. There are large numbers of Prostacyclin/Prostanoids being available for Pulmonary Arterial Hypertension treatment. There are very few numbers of drugs targeting phosphodiesterase for the treatment of Pulmonary Arterial Hypertension. Revatio (Pfizer) and Adcirca (Eli Lilly and CoGSKUnited Corporation) are the two approved phosphodiesterase inhibitors which act by suppressing high blood pressure by releasing nitric oxide. Revatio (Pfizer) helps in improving pulmonary blood flow. Several studies have reported the use of Adcirca (Eli Lilly and CoGSKUnited Corporation) in improving patient compliance due to once a day dosing.
Overall with the increase in the prevalence of this disease along with the approval of the pipeline therapies, it shall create a positive impact on the Pulmonary Arterial Hypertension treatment market during the forecast period (2020–2030).
The launch of the emerging therapies is expected to significantly impact Pulmonary Arterial Hypertension treatment scenario in the upcoming years:-
Drugs covered
1. Aurora-GT 2. Ralinepag 3. Bardoxolone Methyl 4. Rodatristat Ethyl 5. Sotatercept And many others
The key players in Pulmonary Arterial Hypertension market are:
1. United Therapeutics 2. Liquidia Technologies 3. Reata Pharmaceuticals 4. Altavant Sciences 5. Acceleron Pharma And many others
Table of contents
1. Key Insights 2. Executive Summary of Pulmonary Arterial Hypertension 3. SWOT Analysis of Pulmonary Arterial Hypertension 4. Pulmonary Arterial Hypertension Market Overview at a Glance 5. Pulmonary Arterial Hypertension Disease Background and Overview 6. Pulmonary Arterial Hypertension Epidemiology and Patient Population 7. Country Wise-Epidemiology of Pulmonary Arterial Hypertension (PAH) 7.1. The United States 7.2. Germany 7.3. France 7.4. Italy 7.5. Spain 7.6. The United Kingdom 7.7. Japan 8. Pulmonary Arterial Hypertension Treatment Algorithm 9. Unmet Needs 10. Case Studies 11. Organizations related to Pulmonary Arterial Hypertension 12. Pulmonary Arterial Hypertension Marketed Drugs 12.1.Approval and Market Presence 13. Pulmonary Arterial Hypertension Marketed Drugs by Companies 13.1.United Therapeutics Corporation 13.2.Johnson & Johnson 13.3.GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc. 13.4.Bayer AG 13.5. Pfizer 14. Safety and Efficacy of Marketed Drugs 15. Pulmonary Arterial Hypertension Emerging Therapies 15.1. Emerging Drugs Analysis 15.2.Aurora-GT: United Therapeutics 15.3.Ralinepag: United Therapeutics 15.5.Bardoxolone Methyl: Reata Pharmaceuticals 15.6.Rodatristat Ethyl: Altavant Sciences 15.7. Sotatercept: Acceleron Pharma 15.8. PB1064: PhaseBio Pharmaceuticals 15.9. CXA-10: Complexa 16. Other Promising Candidates 16.1. Inhaled Nitric Oxide: Bellerophon Pulse Technologies 16.2.RT234: Respira Therapeutics 17. Pulmonary Arterial Hypertension 7 Major Market Analysis 18. United States 19. EU5 Countries 19.1.Germany 19.2. France 19.3. Italy 19.4. Spain 19.5.United Kingdom 20. Japan 21. Market Drivers 22. Market Barriers 23. Appendix 24. DelveInsight Capabilities 25. Disclaimer 26. About DelveInsight
Request for Detailed TOC: https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pah-market
About DelveInsight DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pah-market